ATE354390T1 - Verfahren zur herstellung einer einzeldosisspritze mit lyophilisierter proteinmischung zur verabreichung eines volumens von weniger als 0,5 ml - Google Patents

Verfahren zur herstellung einer einzeldosisspritze mit lyophilisierter proteinmischung zur verabreichung eines volumens von weniger als 0,5 ml

Info

Publication number
ATE354390T1
ATE354390T1 AT98957272T AT98957272T ATE354390T1 AT E354390 T1 ATE354390 T1 AT E354390T1 AT 98957272 T AT98957272 T AT 98957272T AT 98957272 T AT98957272 T AT 98957272T AT E354390 T1 ATE354390 T1 AT E354390T1
Authority
AT
Austria
Prior art keywords
less
volume
administration
preparing
single dose
Prior art date
Application number
AT98957272T
Other languages
English (en)
Inventor
Karin Limrell
Ebba Florin-Robertsson
Elvy Hoekby
Ulf Nilsson
Anders Stroem
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of ATE354390T1 publication Critical patent/ATE354390T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98957272T 1997-11-28 1998-11-19 Verfahren zur herstellung einer einzeldosisspritze mit lyophilisierter proteinmischung zur verabreichung eines volumens von weniger als 0,5 ml ATE354390T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704405A SE9704405D0 (sv) 1997-11-28 1997-11-28 New syringe

Publications (1)

Publication Number Publication Date
ATE354390T1 true ATE354390T1 (de) 2007-03-15

Family

ID=20409182

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957272T ATE354390T1 (de) 1997-11-28 1998-11-19 Verfahren zur herstellung einer einzeldosisspritze mit lyophilisierter proteinmischung zur verabreichung eines volumens von weniger als 0,5 ml

Country Status (23)

Country Link
US (1) US6152897A (de)
EP (1) EP1034007B1 (de)
JP (1) JP4564652B2 (de)
KR (1) KR100567358B1 (de)
CN (1) CN1156315C (de)
AT (1) ATE354390T1 (de)
AU (1) AU742494B2 (de)
CA (1) CA2311754C (de)
CY (1) CY1106403T1 (de)
CZ (1) CZ300255B6 (de)
DE (1) DE69837159T2 (de)
DK (1) DK1034007T3 (de)
ES (1) ES2281142T3 (de)
HU (1) HUP0004410A3 (de)
MX (1) MXPA00005214A (de)
NO (1) NO324692B1 (de)
NZ (1) NZ505150A (de)
PL (1) PL193243B1 (de)
PT (1) PT1034007E (de)
RU (1) RU2214285C2 (de)
SE (1) SE9704405D0 (de)
SK (1) SK285668B6 (de)
WO (1) WO1999027983A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097007A2 (en) 2011-01-10 2012-07-19 Byeong Seon Chang Compact medication reconstitution device and method
US7959600B2 (en) 2004-12-30 2011-06-14 Byeong S. Chang Container closure delivery system
US20060157507A1 (en) * 2004-12-30 2006-07-20 Chang Byeong S Multi-functional container closure delivery system
US20060144869A1 (en) * 2004-12-30 2006-07-06 Chang Byeong S Container closure delivery system
US8062254B2 (en) * 2008-01-08 2011-11-22 MacLean, LLC Spring driven adjustable oral syringe
GB2498774A (en) 2012-01-27 2013-07-31 Bruce Roser Glass-stabilised biological materials and syringe
TW201605468A (zh) * 2013-09-27 2016-02-16 韓美藥品股份有限公司 長效人類生長激素接合物之製劑
US10201692B2 (en) 2014-09-09 2019-02-12 Byeong Seon Chang Solution delivery device and method
EP3549946A4 (de) * 2016-11-29 2020-10-21 Spiber Inc. Proteinzusammensetzung, verfahren zur herstellung davon und verfahren zur verbesserung der wärmestabilität
CN108498467B (zh) * 2018-05-21 2019-03-05 中山未名海济生物医药有限公司 注射用重组人生长激素无菌粉末及其制备方法
IL272145A (en) * 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic compositions with protein concentrate from conditioned medium of adipose-derived stem cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JP3108077B2 (ja) * 1989-06-08 2000-11-13 住友製薬株式会社 製剤投与器
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5158546A (en) * 1991-08-07 1992-10-27 Habley Medical Technology Corp. Controlled action self-mixing vial
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
SE9202108D0 (sv) * 1992-07-07 1992-07-07 Kabi Pharmacia Ab Dual-chamber injection cartridge
ES2153385T5 (es) * 1992-07-31 2008-09-01 Genentech, Inc. Composicion acuosa a base de hormona del crecimiento humana.
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
FR2752733B1 (fr) * 1996-09-05 1998-11-06 Inst Nat Sante Rech Med Dispositif permeable a base d'hydrogel contenant des cellules vivantes, et ses applications

Also Published As

Publication number Publication date
PL193243B1 (pl) 2007-01-31
EP1034007B1 (de) 2007-02-21
AU1356699A (en) 1999-06-16
WO1999027983A1 (en) 1999-06-10
SK285668B6 (sk) 2007-06-07
KR20010032514A (ko) 2001-04-25
JP4564652B2 (ja) 2010-10-20
NO20002754D0 (no) 2000-05-29
KR100567358B1 (ko) 2006-04-04
CN1280511A (zh) 2001-01-17
CA2311754C (en) 2007-12-18
JP2001524360A (ja) 2001-12-04
MXPA00005214A (es) 2002-04-24
RU2214285C2 (ru) 2003-10-20
NO20002754L (no) 2000-05-29
AU742494B2 (en) 2002-01-03
CZ20001948A3 (cs) 2001-04-11
HUP0004410A3 (en) 2003-05-28
ES2281142T3 (es) 2007-09-16
CA2311754A1 (en) 1999-06-10
EP1034007A1 (de) 2000-09-13
DE69837159D1 (de) 2007-04-05
CZ300255B6 (cs) 2009-04-01
DK1034007T3 (da) 2007-05-21
SK7202000A3 (en) 2001-05-10
CY1106403T1 (el) 2011-10-12
NZ505150A (en) 2002-08-28
CN1156315C (zh) 2004-07-07
DE69837159T2 (de) 2007-11-22
HK1032920A1 (en) 2001-08-10
NO324692B1 (no) 2007-12-03
HUP0004410A2 (hu) 2001-04-28
PL340731A1 (en) 2001-02-26
SE9704405D0 (sv) 1997-11-28
PT1034007E (pt) 2007-04-30
US6152897A (en) 2000-11-28

Similar Documents

Publication Publication Date Title
FI61807B (fi) Foerfarande foer stabilisering av meningokockpolysackarid
ATE354390T1 (de) Verfahren zur herstellung einer einzeldosisspritze mit lyophilisierter proteinmischung zur verabreichung eines volumens von weniger als 0,5 ml
KR850007559A (ko) 조절 펩타이드의 삽입식 제형
BR9609743A (pt) Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
KR890004718A (ko) 안정한 인체 단백질의 제조
EA199900597A1 (ru) Устойчивые жидкие составы интерферона
BR9714015A (pt) Formulações farmacêuticas para distribuição de droga prolongada
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
ATE212220T1 (de) Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen
IL109403A0 (en) Oral drug delivery compositions and methods
CZ108195A3 (en) Stable lyophilized protein-containing preparation and a dosing kit thereof
EP0335133A3 (de) Arzneistoffabgabe mit Hilfe eines Lungentensids zur Absorptionsförderung
AU5909498A (en) Formulations for amylin agonist peptides
JPS54147916A (en) Preparation of urokinase injection
IE882091L (en) Pharmaceutical compositions comprising sometostatin¹analogues
CA2234724A1 (en) Stable pharmaceutical forms of administration containing parathyroid hormone
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
GB1185225A (en) Injectable Adjuvant, method of preparing same and Compositions including such Adjuvant
KR900015749A (ko) 인터루킨-1제형
DE69315388D1 (de) Aus bakteriellen Proteinen bestehender Extrakt, Verfahren zur dessen Herstellung und diesen Extrakt enthaltende pharmazeutische Zusammensetzung
RU2000116647A (ru) Однодозовый шприц, содержащий композицию лиофилизованного белка, для введения объема менее, чем 0,5 мл
DuBuy et al. Relationship between dose size and dose interval of polyinosinic-polycytidylic acid and interferon hyporesponsiveness in mice
EA001579B1 (ru) Лиофилизированная композиция морфогенетического фактора роста кости мр52 человека и способ её получения
JPS646220A (en) Stable freeze-dry herpes virus live vaccine
Lippton et al. Prodepin: a new product of the adrenomedullin (ADM) gene has systemic vasodilator activity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1034007

Country of ref document: EP

REN Ceased due to non-payment of the annual fee